Nonetheless, our findings are consistent with published reports on CSPG4 as a prognostic marker in cancer and provide a rationale for future studies to investigate the effectiveness of CSPG4 directed therapy in chondrosarcoma in vivo. This evidence concerns the gene CSPG4 and cancer.